Physician profile
Joseph M Abraham
NPI 1497934657
$14,136.03
in general payments reported to CMS, 2019-2025
53 companies · $2,282 in 2025
The $2,282 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,769 · 2020: $2,115 · 2021: $2,371 · 2022: $1,891 · 2023: $1,907 · 2024: $1,800 · 2025: $2,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,989.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,912.27 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,817.42 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $1,735.37 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $1,053.45 | 2021-2025 | |
| Glaxosmithkline, LLC. | $774.21 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $625.14 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $591.13 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Sanofi-Aventis U.S. LLC | $486.80 | 2019-2025 | |
| Antares Pharma, INC. | $457.57 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Astellas Pharma US INC | $417.43 | 2019-2022 | |
| Amgen INC. | $390.51 | 2020-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $354.75 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $326.01 | 2019-2023 | Livalo |
| Amarin Pharma, INC. | $318.43 | 2019-2021 | |
| Medtronic, INC. | $226.22 | 2022-2025 | Intellis Adaptivestim, Vanta Adaptivestim, Inpen Smart Insulin Delivery System |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.